Latest Boston Scientific Stories
Endocardial Left Arterial Appendage Closure Devices Offer Significant Revenue Potential, Especially in the US, According to Millennium Research Group TORONTO, June 12, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the anticipated Food and Drug Administration (FDA) approval of Boston Scientific's WATCHMAN device will drive rapid growth in the market for global heart defect closure devices. (Logo:...
NATICK, Mass., May 24, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 38th Annual Deutsche Bank 2013 Healthcare Conference on May 30 in Boston. Mike Mahoney, president and chief executive officer, and Jeff Capello, executive vice president and chief financial officer, will participate in a 35-minute question and answer session regarding the Company beginning at approximately 9:20 a.m. ET. A live webcast of the question and answer...
WIESBADEN, Germany, May 21, 2013 /PRNewswire/ -- Medical device manufacturer OrbusNeich Medical Inc. and its subsidiary, OrbusNeich Medical GmbH (collectively "OrbusNeich") today announced that it has enforced the seizure of over 190 stent systems from Boston Scientific Corporation (NYSE: BSX) in connection with its patent infringement proceedings in the Dusseldorf Regional Court. The products were found on May 15, 2013, at the premises of Boston Scientific Medizintechnik GmbH in...
Industry-Leading Battery Life Reduces the Frequency of Replacement Surgery NATICK, Mass., May 10, 2013 /PRNewswire/ -- New data from 100,438 patients with Boston Scientific Corporation (NYSE:BSX) implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) followed in the LATITUDE(TM)( )Patient Management System demonstrate the battery life of Boston Scientific single-chamber ICDs, dual-chamber ICDs and CRT-Ds are projected to last an...
NATICK, Mass., May 8, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Bank of America Merrill Lynch 2013 Healthcare Conference on May 15 in Las Vegas. Jeff Capello, executive vice president and chief financial officer, will participate in a 30-minute question and answer session regarding the company beginning at approximately 8:40 a.m. PT. A live webcast of the question and answer session will be available to interested parties via...
New ICD device technology is changing the CRM market for a population with heart disease on the rise. Vancouver, Canada (PRWEB) April 16, 2013 Heart failure affects over five million people annually in the U.S., and is the most costly cardiovascular illness with upwards of $30 billion spent on managing it each year. According to a new report by iData Research, the leading global authority in medical device and pharmaceutical market research, the U.S. cardiac rhythm management (CRM),...
NATICK, Mass., April 10, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2013 on Thursday, April 25, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, president and chief executive officer, and Jeff Capello, executive vice president and chief financial officer. A live webcast of the conference call will be available via Boston Scientific's website. Webcast...
CHICAGO, March 14, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Boston Scientific (NYSE:BSX), Abbott Laboratories (NYSE:ABT), Cyberonics Inc. (Nasdaq:CYBX), Given Imaging. (Nasdaq:GIVN) and Aflac Inc. (NYSE:AFL). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)...
WATCHMAN® Device Continues to Demonstrate Positive Clinical Outcomes for Patients with Atrial Fibrillation NATICK, Mass., March 9, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces the preliminary analysis of the PREVAIL clinical trial data is now available on TCTMD at http://www.tctmd.com/show.aspx?id=118115. PREVAIL evaluates the safety and efficacy of the WATCHMAN® Left Atrial Appendage (LAA) Closure device in patients with nonvalvular atrial...
First Presentation of the Preliminary Results of All Three Co-Primary Endpoints to be Revealed During The American College of Cardiology 2013 Annual Scientific Sessions NATICK, Mass., March 6, 2013 /PRNewswire/ -- The Boston Scientific Corporation (NYSE: BSX) PREVAIL clinical trial results will be presented in a Late-Breaking Clinical Trial presentation at the 62nd Annual Scientific Sessions of the American College of Cardiology, and will include all three co-primary endpoints that...
